arrow
H

Hartmut Döhner

ulm university hospital
H指数:146
被引数:11.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

FLT3-ITD微小克隆在AML中的预后影响:EHA AML专业化工作组研究

2026-11-010
PRE
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

DECIDER-2:一项前瞻性随机多中心III期临床试验,评估地西他滨联合维奈克拉在所有-trans维甲酸或安慰剂中给予急性髓系白血病患者的疗效,这些患者不适合诱导化疗

2026-08-050
OA
Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients

利用长读长测序技术实现急性髓系白血病患者的快速且可重复的核型分析

2026-06-290
OA
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia

FLT3-ITD突变急性髓系白血病中髓系发育异常相关基因突变的预后影响

Leukemia
IF13.4
2026-02-090
OAAI
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study

解析具有预后意义的NPM1突变成人急性髓系白血病的共突变模式——一项HARMONY研究

Leukemia
IF13.4
2026-01-140
OA
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial

随机II期DECIDER试验中,急性髓系白血病持续应用脱氧胞苷类似物为基础治疗后,获得性耐药时的遗传和表观遗传改变

Leukemia
IF13.4
2025-10-070
OA
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

肾疾病在应用Venetoclax为基础的低强度疗法治疗的初诊急性髓系白血病中的预后作用

2025-09-230
OAAI
A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE

比较治疗相关和原发性MDS的1590例与4738例患者预后变量和细胞遗传学异常的比较,包括MDS阶段治疗的影响

2025-09-010
PRE
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML

AGILE研究中,阿扎胞苷联合伊沃西登ib与安慰剂在 Newly Diagnosed IDH1-mutated AML中的长期结果

2025-07-280
OAAI
A non-coding mutation within the NOTCH1 gene initiates oncogenic NOTCH signaling via wild type NICD stabilization in CLL

NOTCH1基因内的非编码突变通过野生型NICD的稳定化在CLL中启动癌基因NOTCH信号通路

Blood
IF23.1
2025-07-120
OAAI
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia

髓系发育不良相关基因突变克隆性表达在急性髓系白血病中的预后影响

LEUKEMIA
IF13.4
2025-04-280
OA
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (vol 149, pg 913, 2022)

德国卓越中心在COVID-19大流行第一年中的癌症护理(vol 149, pg 913, 2022)

2025-01-180
OA
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report

利用Li-Fraumeni综合征患者体细胞癌基因驱动突变:铺就精准医学之路:一个病例报告

2025-01-160
OA
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
2024-12-030
OAAI
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

10年随访研究:CALGB 10603/Ratify试验中,年龄18-60岁新诊断FLT3突变急性髓系白血病患者的米哚妥林与安慰剂联合强化化疗的比较

BLOOD
IF23.1
2024-11-050
PRE
The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations

伴FLT3-ITD突变的急性髓系白血病中,髓系发育不良相关基因突变对预后的影响

BLOOD
IF23.1
2024-11-050
PRE